ONCODESIGN: insider trades · France · AMF

About ONCODESIGN

ONCODESIGN is now a recognized player in drug discovery and precision medicine, originally founded in Dijon in 1995 by Philippe Genne. The company began as a pharmacology services business and gradually built an integrated scientific platform spanning target identification, candidate selection, and translational research, with a strong historical focus on oncology. For many years, the group combined two complementary activities: a research-services business serving pharmaceutical and biotech clients, and a proprietary biotech pipeline. In July 2022, the group announced the separation of these two business lines, creating Oncodesign Precision Medicine (OPM) for the biotech/AI activities while retaining the services business under Oncodesign Services. From a business-model perspective, Oncodesign Services operates as a contract research organization specializing in drug discovery and preclinical research. Its service offering covers medicinal chemistry, in vitro biology, pharmacokinetics, bioanalysis, and in vivo pharmacology. The company is positioned around high-unmet-need therapeutic areas, particularly oncology, but also inflammation and infectious diseases. Its value proposition is built on strong scientific integration and close collaboration with pharmaceutical companies, biotech firms, academic institutions, and public research organizations. OPM, meanwhile, develops proprietary therapeutic assets focused on resistant and metastatic cancers, leveraging precision-medicine and artificial-intelligence capabilities. The group benefits from established recognition in the European life-sciences ecosystem. Its historical base in Dijon provides access to a solid hospital-university environment, while its development footprint also includes additional locations in the greater Paris area and international links. Recent public disclosures highlight sustained partnering and development activity, including programs in oncology, neurology, and inflammatory diseases. A notable milestone was the 2024 acquisition of ZoBio by Oncodesign Services, which strengthened the company’s capabilities in small-molecule discovery and translational research. Overall, ONCODESIGN is a highly specialized, technology-driven company operating in a niche but strategically important segment of the healthcare and pharmaceutical value chain.